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Abstract
Background: Diagnosis of ductal carcinoma in situ (DCIS) in breast cancer cases is challenging for pathologist due
to a variety of in situ patterns and artefacts, which could be misinterpreted as stromal invasion. Microinvasion is
detected by the presence of cytologically malignant cells outside the confines of the basement membrane and
myoepithelium. When malignant cells invade the stroma, there is tissue remodeling induced by perturbed stromal-
epithelial interactions. Carcinoma-associated fibroblasts (CAFs) are main cells in the microenvironment of the
remodeled tumor-host interface. They are characterized by the expression of the specific fibroblast activation
protein-alpha (FAP-a), and differ from that of normal fibroblasts exhibiting an immunophenotype of CD34. We
hypothesized that staining for FAP-a may be helpful in determining whether DCIS has microinvasion.
Methods: 349 excised breast specimens were immunostained for smooth muscle actin SMA, CD34, FAP-a, and
Calponin. Study material was divided into 5 groups: group 1: normal mammary tissues of healthy women after
plastic surgery; group 2: usual ductal hyperplasia (UDH); group 3: DCIS without microinvasion on H & E stain; group
4: DCIS with microinvasion on H & E stain (DCIS-MI), and group 5: invasive ductal carcinoma (IDC). A comparative
evaluation of the four immunostains was conducted.
Results: Our results demonstrated that using FAP-a and Calponin adjunctively improved the sensitivity of
pathological diagnosis of DCIS-MI by 11.29%, whereas the adjunctive use of FAP-a and Calponin improved the
sensitivity of pathological diagnosis of DCIS by 13.6%.
Conclusions: This study provides the first evidence that immunostaining with FAP-a and Calponin can serve as a
novel marker for pathologically diagnosing whether DCIS has microinvasion.
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Background
With widespread use of mammographic screening, many
cases of breast cancer are now detected at an early stage.
This has led to an increased incidence of not only in situ
but also microinvasive carcinoma. Today, ductal carci-
noma in situ (DCIS) accounts for 25% to 30% of breast
cancer cases that are detected in the population-screening
programs [1,2]. In contrast, DCIS with microinvasion
(DCIS-MI) is an uncommon pathologic entity that repre-
sents < 1% of breast cancers [2,3].
In the histological examination of DCIS-MI, the main
objective is to identify invasive focus or foci, because the
therapy for patients with pure in situ carcinoma differs
from that of patients with in situ carcinoma associated
with microinvasive breast cancer [4]. Microinvasion is
detected with the presence of cytologically malignant cells
outside the confines of the basement membrane and
myoepithelium [5]. Histological evaluation of minuscule
foci of microinvasion is often difficult for the pathologist,
because a variety of in situ patterns and artefacts could be
misinterpreted as stromal invasion [6-9]. However, during
the carcinogenesis of DCIS-MI, there is tissue remodeling
induced by the perturbed stromal-epithelial interactions.
Stromal fibroblasts in the microenvironment of the remo-
deled tumor-host interface are known as carcinoma-asso-
ciated fibroblasts (CAFs) [9]. They are the main cells in
the stroma and are characterized by the expression of the
specific fibroblast activation protein-alpha (FAP-a),
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bit a CD34 immunophenotype [10,11].
The purpose of this study is to screen the expression
of FAP-a around minuscule foci of microinvasion and
investigate its functional role in the immunohistochem-
istic diagnosis of DCIS-MI.
Methods
We used the surgical oncology breast cancer database to
retrospectively evaluate 349 patients who had undergone
mastectomy between March 1994 and March 2010. Archi-
val material was obtained from the files of the Department
of Pathology and Medical Records Room, the Forth
Affiliated Hospital of Jinan University, Guangzhou, China.
All specimens were formalin-fixed and paraffin-embedded.
All the available slides were reviewed blindly by five
pathologists simultaneously and a consensus report of the
diagnosis was obtained. To test the validity of immunos-
tains and for comparative evaluation, study cases were
divided into 5 groups: group 1: normal mammary tissues
from healthy women after plastic surgery, 20 cases; group
2: usual ductal hyperplasia (UDH), 72 cases; group 3:
DCIS without microinvasion on H& E stain, 109 cases;
group 4: DCIS with microinvasion on H & E stain (DCIS-
MI) utilizing the AJCC criteria, 81 cases; group 5: invasive
ductal carcinoma (IDC), 67 cases. This study was approved
by our hospital review board.
Four sections of 4μ thickness were cut from the paraffin
blocks of those breast lesions. Consecutive sections were
used for a better comparison between morphology and
protein expression. Immunohistochemical staining for
CD34, smooth muscle actin (SMA), Calponin, and FAP-a
was done as described elsewhere [12]. The primary antibo-
dies against FAP-a (clone 427819, 1:50 dilution) and SMA
(clone 1A4, 1:100 dilution) were obtained from R & D sys-
tems. The primary antibodies against Calponin (clone
CALP, 1:50 dilution) was obtained from Abcam company,
while that for CD34 (clone QBEnd10, 1:100 dilution) was
obtained from Dako Corporation. Appropriate positive
and negative controls were run in each case. In group 1,
group 4, and group 5, staining was interpreted as positive
only when cytoplasm staining was detected in more than
10% of stromal firoblasts in the microenvironment of the
tumor-host interface. In group 2 and 3, staining was inter-
preted as positive only when more than 10% of stromal fir-
oblasts cells in the microenvironment of the tumor-host
interface or at the invasive front showed cytoplasm stain-
ing. Positive staining for Calponin in the myoepithelial
cells (MECs) of breast duct was interpreted as continu-
ously, discontinuously, scattered positive or negative.
Results
Distinct immunohistochemical staining of CD34, SMA,
Calponin and FAP-a was detected in all the 349 cases of
this study. The association of the immunophenotype of
stromal fibroblasts with various clinicopathological para-
meters is listed in Table 1.
Group 1 (normal mammary tissues): As shown in
Figure 1, CD34 protein expression was detected mainly
in the cytoplasm of stromal fibroblasts in 18 (90%) of 20
cases. SMA protein expression was detected mainly in
the cytoplasm of stromal fibroblasts in 4 (20%) of the
total 20 cases. None of the 20 cases in this group
showed positivity for FAP-a in the stroma. Calponin
p r o t e i ne x p r e s s i o nw a sd e t ected continuously in the
cytoplasm of MECs of breast duct in all the 20 cases.
Group 2 (usual ductal hyperplasia, UDH): As shown in
Figure 2, CD34 protein expression was detected mainly
in the cytoplasm of stromal fibroblasts in 68 (94.44%) of
the 72 cases. SMA protein expression was detected
mainly in the cytoplasm of stromal fibroblasts in 11
(15.28%) of 72 cases. But only one (1.39%) of the 72
cases showed positivity for FAP-a in the stromal fibro-
blasts. Calponin protein expression was detected con-
tinuously in the cytoplasm of MECs of breast duct in all
the cases.
Group 3 (DCIS without microinvasion on H & E stain):
As shown in Figure 3, CD34 protein expression was
detected mainly in the cytoplasm of stromal fibroblasts in
13 (11.93%) of the total 109 cases. SMA protein expres-
sion was detected mainly in the cytoplasm of stromal
fibroblasts in 81 (74.31%) of 109 cases. 21 (19.27%) of
109 cases showed fibroblasts that were FAP-a positive in
the microenvironment of the tumor-host interface. Cal-
ponin protein expressed continuously in the cytoplasm of
MECs of breast duct in 87 (79.82%) of 109 cases, whereas
3 (2.75%) cases showed scattered expression of Calponin.
On the other hand, 19 (14.73%) cases showed Calponin
n e g a t i v e .I tw a sw o r t hn o t i n gt h a to ft h e1 9c a s e s ,e s p e -
cially in the region of the tumor-host interface where
Calponin was negatively expressed, 19 (100%) cases
showed FAP-a positive and 12 (63.16%) showed SMA
positive, but 17 (89.47%) of these 19 cases reported nega-
tive for CD34 protein. Reexamination of these 19 cases
was done blindly by the five pathologists using the tech-
nique of H & E and immunohistochemical staining. This
led to the pathologists to change the diagnosis of 18 of
these 19 cases to DCIS-MI.
Group 4 (DCIS with microinvasion on H & E stain,
DCIS-MI): As shown in Figure 4, stromal fibroblasts in
the tumor-host interface at the invasive front of DCIS-
MI lesions were diagnosed. 16 (19.75%) of 81 cases
showed CD34 positivity, whereas 77 (95.06%) of 81 cases
s h o w e dS M Ap o s i t i v i t y ,a n d6 7( 8 2 . 7 2 % )o f8 1c a s e s
showed significant FAP-a positivity. In the tumor-host
interface at the invasion front of all the 81 cases, 64
(79.01%) showed Calponin negative, 3 (3.70%) showed
Calponin expression as scattered, and 17 (20.99%)
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artifactary and inflammatory remodeled stroma. There-
fore, reexamination of the 17 cases was done on the basis
of H & E and immunohistochemical staining. This led to
t h ep a t h o l o g i s t sc h a n g et h ed i a g n o s i so f1 3o ft h e s e1 7
cases to DCIS without microinvasion.
Group 5 (invasive ductal carcinoma, IDC): As shown in
Figure 5, stromal fibroblasts of 7 (10.45%) of 67 IDC cases
showed CD34 positivity, while 63(94.03%) of 67 IDC cases
showed significant SMA positivity. Moreover, all cases of
IDC showed intense FAP-a staining of stromal fibroblasts.
Calponin protein expression was detected sporadically
positive or negative in the stroma of all the IDC cases.
Discussion
DCIS-MI is a rare histological subtype of breast carci-
noma. The cells deemed to be invasive must be distribu-
ted either singly or as small groups in a non-organoid
pattern having irregular shapes that are reminiscent of
the conventional invasive carcinoma with no particular
orientation [4]. In the fourth edition of the European
guidelines for quality assurance in breast cancer screening
and diagnosis published in 2006 [13] and in the 2010 edi-
tion of the American Joint Committee on Cancer staging
system [14], the diagnosis of microinvasive carcinoma of
the breast (T1mic) is applied to those invasive carcino-
mas with no focus measuring > 1 mm. The current sta-
ging manual states that microinvasive carcinoma is
nearly always encountered in a setting of DCIS [or, less
often, lobular carcinoma in situ (LCIS)] in which small
foci of tumor cells have invaded through the basement
membrane into the surrounding stroma [15]. Although
some authors have required that such invasive foci
extend beyond terminal ductal lobular unit (TDLU)
stroma into the interlobular tissue [16], this is not sup-
ported by the ultrastructural confirmation of intralobular
capillaries in close proximity to the delimiting fibroblastic
layer of terminal ducts [17,18]. Furthermore, DCIS often
unfolds the TDLU externalizing the once intralobular
stroma. Any distinctive feature of the TDLU stroma is
often masked by an inflammatory infiltrate and/or stro-
mal fibrosis. In the presence of DCIS, the TDLU stroma
may not be distinguishable from the interlobular stroma
[19].
In this study, all the cases were classified within the con-
text of a study and were classified by the same pathologists
repeatedly. Pathologists made the pathological diagnosis
mainly based on morphological characteristics and the
immunohistochemical staining according to that diagnos-
tic criteria and the pathological diagnosis conclusion was
unaffected by the archived diagnoses which had already
reported to the clinician. In order to minimize the diag-
nostic subjectivity, we asked five experienced pathologists
who had received the same training and mastered the
diagnostic criteria, to review all the available slides and
asked them to classify double-blindly. If their diagnoses
Table 1 Levels of markers’ expression in relation to clinicopathologic variables
Diagnostic group Total cases CD34 SMA Calponin FAP-a
Positive % Positive % Positive %
Group 1 20 19 95.00 2 10.00 continuous (20) 0 0
Group 2 72 68 94.44 11 15.27 continuous (72) 1 1.39
Group 3 109 13 11.93 81 74.31 continuous (87)
discontinuous (3)
negative (19)
21 19.27
Group 4 81 16 19.75 77 95.06 continuous (0)
discontinuously (17)
scattered (3)
negative (64)
67 82.72
Group 5 67 7 10.45 63 94.03 scattered (11)
negative (56)
67 100
Figure 1 Representative immunohistochemical staining results (magnification × 100). (a) HE; (b) CD34 positive; (c) SMA negative; (d)
Calponin continuously positive; (e) FAP-a negative. The virtual slide for this article can be found here: http://www.diagnosticpathology.diagnomx.
eu/vs/7086274655925365/1.
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final diagnosis. In this way, we kept our diagnostic results
reliable.
But various patterns in DCIS may be mis-interpreted as
stromal invasion, including the cases where there is degen-
erative appearance of the dislodged tumour cells, chronic
inflammatory reaction, crush artefacts, cautery effects, and
distortion or entrapment of involved ducts or acini by
fibrosis [6-8,20]. As reported earlier [4], it is difficult to
determine whether in-situ breast carcinoma is associated
with microinvasion, even with the help of immunohisto-
chemistry techniques.
The absence of basement membrane material around
nests of tumor cells defines the process as being invasive.
Immunohistochemistry for basement membrane compo-
nents (laminin and type IV collagen) is helpful in detect-
ing the presence or absence of basement membrane.
However, cells of invasive cancer can still synthesize
components of basement membrane around invasive
nests. Therefore, the use of basement membrane markers
for the detection of stromal invasion is not recommended
[4,21].
The presence of MECs around nests of carcinoma cells
defines the process as being in situ. Immunohistochemis-
try for P63, S100 and smooth-muscle myosin heavy chain
(SMM-HC) for MECs has been used in determining
whether a process represents in situ carcinoma or stro-
mal invasion. But, those antibodies occasionally form an
apparently discontinuous myoepithelial layer around
nests of in situ lesions, and they also react with a small
but significant subset of breast carcinoma tumor cells
[4,21,22]. While MECs are retained around ductal-lobu-
lar spaces containing DCIS, molecular studies have indi-
cated that MECs surrounding with mammary ducts and
lobular acini have important roles in the development
and physiology of normal mammary glands, including
maintenance of the basement membrane around ductal-
lobular structures, providing a physical barrier between
epithelial cells and the surrounding stroma, and main-
taining epithelial cell polarity. Furthermore, experimental
evidence has indicated that MECs produce factors that,
through paracrine effects, to inhibit tumor growth, inva-
sion, and angiogenesis [23-26]. Recently, more and more
attention has been paid to the potential role of the MECs
in the progression of DCIS to invasive breast carcinoma.
T h o u g hM E C st h a ts u r r o u n ds p a c e si n v o l v e db yD C I S
differ substantially from normal MECs in several respects
[25-29], Calponin is a contractile element that expressed
in differentiated smooth muscle cells and is highly sensi-
tive to normal noninvasive MECs and breast MECs [30].
In this study, our diagnosis mainly based on morpholo-
gical characteristics, while refering the expression of
SMA, CD34 and FAP-a of stromal fibroblasts besides
integrity of MECs. CD34 is a transmembrane glycopro-
tein expressed by haematopoietic stem cells, endothelial
cells and mesenchymal cells in different tissues including
breast that is thought to be involved in the modulation of
cell adhesion and signal transduction. CD34
+ fibrocytes/
fibroblasts derive from myeloid precursors, besides its
function as a matrix-production cell, it is a potent anti-
gen-presenting cell and therefore it has been claimed that
CD34
+ may play a role in host response to tissue damage
Figure 2 Representative immunohistochemical staining results (magnification × 100). (a) HE; (b) CD34 positive; (c) SMA negative; (d)
Calponin continuously positive; (e) FAP-a negative. The virtual slide for this article can be found here: http://www.diagnosticpathology.diagnomx.
eu/vs/7086274655925365/2.
Figure 3 Representative immunohistochemical staining results (magnification × 200).( a )H E ;( b )C D 3 4n e g a t i v e ;( c )S M Ap o s i t i v e ;( d )
Calponin continuously positive; (e) FAP-a positive. The virtual slide for this article can be found here: http://www.diagnosticpathology.diagnomx.
eu/vs/7086274655925365/3.
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or absence of this population of cells might be useful in
distinguishing benign from malignant lesions of the skin
[34] and gastrointestinal tract [35,36]. The stroma of nor-
mal mammary gland contains many CD34 positive fibro-
blasts/fibrocytes and the presence of stromal positive
CD34 fibroblasts has been shown to be associated with
benign lesions [31,32,37]. In malignant tumors it was
noticed a loss of CD34 positive cells and gain of smooth
muscle cell actin positive myofibroblasts [33,38,39] and
this is in keeping with our findings. In our study, stromal
fibroblasts in the normal mammary tissues and UDH
showed mainly immunophenotype of SMA
-CD34
+FAP-
a
-. In the tumor-host interface of DCIS and IDC, stromal
fibroblasts exhibited mainly immunophenotype of SMA
+CD34
-FAP-a
+. In the tumor-host interface of DCIS-MI,
stromal fibroblasts exhibited SMA
-CD34
+FAP-a
-,h o w -
ever, in the tumor-host interface at the invasive front of
DCIS-MI lesions, stromal fibroblasts exhibited mainly
immunophenotype of SMA
+CD34
-FAP-a
+.
To the best of our knowledge, there is no study evalu-
ating the role of FAP-a with reference to microinvasion
of DCIS.
FAP-a is a cell surface glycoprotein belonging to the ser-
ine protease family, is expressed by the CAFs in over 90%
of human epithelial cancers including breast, ovarian,
bladder, colorectal, and lung cancers, but it is not
expressed in epithelial cancer cells, normal fibroblasts, and
other normal tissues except the transient expression in
healing wounds [40-45]. In this study, at the invasion front
of all the DCIS-MI, stromal fibroblasts expressed FAP-a
and there was significant statistical difference in the
expression of FAP-a protein in groups 3 and 4, but no sta-
tistical difference was reported in the FAP-a protein
expression for groups 4 and 5. FAP-a plays an important
role in tumor growth and metastasis, as its expression on
CAFs may create an environment permissive for cancer
growth and invasion via collagenase and dipeptidyl pepti-
dase activities [10,11,46,47]. We suggested the possibility
of FAP-a promoting the formation of microemboli that
facilitates the metastasis of breast cancer. Thus, FAP-a
can serve as a novel marker for pathologically determining
whether DCIS has microinvasion.
Based on immunohistochemical staining, we found that
some initally diagnosed DCIS-MI had discontinuously
MECs around the so-called invasive foci without stromal
reaction (SMA
-CD34
+FAP-a
-). In such condition, we
changed the original diagnosis of DCIS-MI to DCIS. In
the same way, some of the DCIS cases were rediagnosed
as DCIS-MI. In the study group 3, at the invasive front of
the 18 re-examined DCIS-MI, 12 cases showed SMA
positive, while 5 cases showed CD34 positive. 17 cases
showed Calponin negative, and one Calponin negative
case was still diagnosed as DCIS, but all of the 18 re-
examined cases showed negative expression of FAP-a in
the stromal fibroblasts. The sensitivity of SMA, CD34,
Calponin and FAP-a in diagnosis of DCIS is 75%, 78%,
98% and 98%, respectively. In the study group 4, in the
tumor-host interface of the 13 re-examined DCIS cases,
8 cases showed SMA positive, while 7 cases showed
CD34 negative. 4 cases showed Calponin negative, and
12 cases showed FAP-a negative. The sensitivity of SMA,
CD34, Calponin and FAP-a in diagnosis of DCIS-MI is
77%, 71%, 97% and 98%, respectively. In our study, using
Figure 4 Representative immunohistochemical staining results (magnification × 200).( a )H E ;( b )C D 3 4n e g a t i v e ;( c )S M Ap o s i t i v e ;( d )
Calponin negative; (e) FAP-a positive. The virtual slide for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
7086274655925365/4.
Figure 5 Representative immunohistochemical staining results (magnification × 200).( a )H E ;bC D 3 4n e g a t i v e ;( c )S M Ap o s i t i v e ;( d )
Calponin negative; (e) FAP-a positive. The virtual slide for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
7086274655925365/5.
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ity of pathological diagnosis of DCIS by 13.6%, whereas
the adjunctive use of Calponin and FAP-a improved the
sensitivity of pathological diagnosis of DCIS-MI by
11.29%.
In conclusion, this study provides the first evidence
that immunostaining with FAP-a and Calponin can
serve as a novel marker for pathologically diagnosing
whether DCIS has microinvasion. We also suggested the
possibility of FAP-a promoting the formation of micro-
emboli, which facilitate the metastasis of breast cancer.
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